---
title: "BUZZ-China's Ascletis hits 6-year peak on good results for weight loss drug"
description: "Shares of Ascletis Pharma Inc surged 8.7% to HK$7.99, marking a six-year peak following positive Phase 1B results for its weight loss drug ASC47. The stock is on track for its largest one-day gain sin"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/231482690.md"
published_at: "2025-03-12T06:31:17.000Z"
---

# BUZZ-China's Ascletis hits 6-year peak on good results for weight loss drug

> Shares of Ascletis Pharma Inc surged 8.7% to HK$7.99, marking a six-year peak following positive Phase 1B results for its weight loss drug ASC47. The stock is on track for its largest one-day gain since March 3 and has risen for three consecutive sessions. The U.S. FDA has approved the Investigational New Drug application for ASC47 in combination with semaglutide for obesity treatment. Year-to-date, the stock has increased by 144.2%. Meanwhile, Hong Kong's healthcare index and Hang Seng Index both fell by 0.1%.

Shares of Chinese pharmaceutical products developer Ascletis Pharma Inc (1672.HK) jump 8.7% to HK$7.99, their highest since March 2019

Stock on course for the biggest one-day gain since March 3; on track for third straight session of rise

Ascletis announces positive topline results of Phase 1B studies of weight loss drug candidate ASC47 monotherapy in Australia

Says U.S. Food and Drug Administration has cleared the U.S. Investigational New Drug application for ASC47 in combination with semaglutide for the treatment of obesity

Hong Kong’s healthcare index (.HSCIH) and Hang Seng Index (.HSI) both slip 0.1%

Stock up 144.2% YTD

### Related Stocks

- [01672.HK - ASCLETIS-B](https://longbridge.com/en/quote/01672.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Ascletis Pharma to Raise HK$835 Million via Share Placement to Fund Obesity Drug Trials | Ascletis Pharma Inc. plans to raise approximately HK$835 million through a share placement of 69,256,000 new shares at H | [Link](https://longbridge.com/en/news/274573426.md) |
| Assessing Ascletis Pharma (SEHK:1672) Valuation After New ASC37 Obesity Candidate Advances Toward FDA IND Filing | Ascletis Pharma (SEHK:1672) has advanced its ASC37 obesity candidate towards an FDA IND filing by 2026, marking a signif | [Link](https://longbridge.com/en/news/268739926.md) |
| Efforts to build track in Tellico Plains honoring champion runner stall | Efforts to build a track in Tellico Plains in honor of champion runner Darrah Wiseman have stalled after more than a yea | [Link](https://longbridge.com/en/news/276083400.md) |
| Deadliest jobs in America revealed | In 2024, the U.S. recorded 5,070 fatal work injuries, a 4% decrease from 2023. Truck drivers and construction workers we | [Link](https://longbridge.com/en/news/276462715.md) |
| Sai Life Sciences To Recruit 700+ Professionals In FY27 | Sai Life Sciences plans to recruit over 700 professionals in FY27 to enhance its capabilities in drug discovery, develop | [Link](https://longbridge.com/en/news/276428903.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.